Loading...
•
Jun 30
Akero Q2 2025 Earnings Report
Akero Therapeutics reported Q2 2025 results with a net loss of $70.5M and an EPS of -$0.86.
Key Takeaways
Akero Therapeutics posted a Q2 2025 net loss of $70.5 million, or -$0.86 per share, driven by increased R&D spending for Phase 3 trials. The company ended the quarter with $1.086 billion in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2028.
Net loss for Q2 2025 was $70.5 million, compared to $56.0 million in Q2 2024.
EPS was -$0.86, compared to -$0.81 in Q2 2024.
R&D expenses increased to $69.3 million due to Phase 3 trial activities.
Cash and marketable securities totaled $1.086 billion, providing runway into 2028.
Akero
Akero
Forward Guidance
Akero expects to report preliminary results from the SYNCHRONY Real-World Phase 3 trial in the first half of 2026 and SYNCHRONY Histology results in the first half of 2027, with cash runway into 2028.
Positive Outlook
- Preliminary SYNCHRONY Real-World results expected in 1H 2026.
- SYNCHRONY Histology readout anticipated in 1H 2027.
- Cash runway expected to last into 2028.
- Positive Phase 2b SYMMETRY results published in NEJM.
- EASL 2025 presentations reinforced EFX's antifibrotic potential.
Challenges Ahead
- Continued operating losses driven by R&D investment.
- No current revenue generation from product sales.
- Dependency on clinical trial success for future growth.
- High costs for Phase 3 trials and manufacturing.
- Potential regulatory risks impacting trial timelines.